Rotavirus vaccine RIX4414 (Rotarix™): A pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries

PharmacoEconomics

Volumn 29, Issue 5, 2011, Pages 439-454

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Children; Gastroenteritis; Infants; Rotavirus infections

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE; SIMIAN ROTAVIRUS VACCINE;

APPETITE DISORDER; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; COUGHING; DEVELOPED COUNTRY; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; ECONOMIC EVALUATION; EMBASE; FLATULENCE; GASTROENTERITIS; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH STATUS; HEALTH SURVEY; HUMAN; INTESTINE INFECTION; INTUSSUSCEPTION; IRRITABILITY; MEDICAL LITERATURE; MEDLINE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINORRHEA; ROTAVIRUS GASTROENTERITIS; ROTAVIRUS INFECTION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VACCINATION; VOMITING;

CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; GASTROENTERITIS; HEALTH CARE COSTS; HUMANS; INFANT; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 79955101797     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11207130-000000000-00000     Document Type: Article

References (79)

1. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003 May; 9 (5): 565-72 (Pubitemid 36529515)
2. Leung AK, Kellner JD, Davies HD. Rotavirus gastroenteritis. Adv Ther 2005 Sep 31; 22 (5): 476-87 (Pubitemid 43130865)
3. Cortese MM, Parashar UD, Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009 Feb 6; 58 (RR-2): 1-25
4. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006 Aug 11; 55 (RR-12): 1-13
5. Gray J, Vesikari T, VanDamme P, et al. Rotavirus. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl. 2: S24-31 (Pubitemid 351644167)
6. Clark HF, Offit PA. Vaccines for rotavirus gastroenteritis universally needed for infants. Pediatr Ann 2004 Aug; 33 (8): 536-43 (Pubitemid 39079062)
7. Parashar UD, Gibson CJ, Bresse JS, et al. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006 Feb; 12 (2): 304-6
8. Soriano-GabarroM,Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006; 25 Suppl. 1: S7-11
9. Bhan MK, Lew JF, Sazawal S, et al. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993 Aug; 168 (2): 282-7 (Pubitemid 23210600)
10. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996 Oct 3; 335 (14): 1022-8 (Pubitemid 26338732)
11. Bishop RF, BarnesGL, Cipriani E, et al.Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983 Jul 14; 309 (2): 72-6 (Pubitemid 13063589)
12. Velazquez FR. Protective effects of natural rotavirus infection. Pediatr Infect Dis J 2009 Mar; 28 (3 Suppl.): S54-6
13. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15 (1): 29-56 (Pubitemid 40070041)
14. Van Damme P, Giaquinto C, Maxwell M, et al. Distribution of rotavirus genotypes in Europe, 2004-2005: the REVEAL Study. J Infect Dis 2007 May 1; 195 Suppl. 1: S17-25
15. Diez-Domingo J, Baldo JM, Patrzalek M, et al. Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis among children aged less than 5 years in six European countries. Eur J Pediatr 2011; 170 (2): 213-22
16. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl. 2: S38-48 (Pubitemid 351644169)
17. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics 2009 May; 123 (5): 1412-20
18. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008 May; 46 (5): 615-8
19. No authors listed. Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. Wkly Epidemiol Rec 2009 Aug 7; 84 (32): 325-32
20. Rotarix (rotavirus vaccine, live, oral) US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2011 Feb
21. McCormack PL, Keam SJ. Rotavirus vaccine RIX4414 (Rotarix): a review of its use in the prevention of rotavirus gastroenteritis. Paediatr Drugs 2009; 11 (1): 75-88
22. Rotarix. Summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ hu man/000639/WC500054789.pdf [Accessed 2011 Mar 14]
23. Giaquinto C, van Damme P. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study. Scand J Infect Dis 2010; 42 (2): 142-7
24. Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007 May 1; 195 Suppl. 1: S4-16
25. Giaquinto C, Van Damme P, Huet F, et al. Costs of community- acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis 2007 May 1; 195 Suppl. 1: S36-44
26. Standaert B, Harlin O, DesselbergerU. The financial burden of rotavirus disease in four countries of the European Union. Ped Infect Dis J 2008 Jan; 27 (1): S20-7
27. Grimwood K, Lambert SB, Milne RJ. Rotavirus infections and vaccines: burden of illness and potential impact of vaccination. Pediatr Drugs 2010; 12 (4): 235-56
28. Monto AS. Epidemiology of influenza. Vaccine 2008 Sep 12; 26 Suppl. 4: D45-8
29. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus activity: United States, July 2007- December 2008. MMWR Morb Mortal Wkly Rep 2008 Dec 19; 57 (50): 1355-8
30. Armengaud JB, El Hajje MJ, Moulin F, et al. Simultaneous outbreaks of rotavirus and respiratory syncytial virus in Paris: a 12-year survey [in French]. Med Mal Infect 2007 May; 37 (5): 262-5 (Pubitemid 46754703)
31. Maille L, Beby-Defaux A, Bourgoing A, et al. Nosocomial infections due to rotavirus and respiratory syncytial virus in pediatric wards: a 2-year study [in French]. Ann Biol Clin (Paris) 2000; 58: 601-6
32. Gleizes O, Desselberger U, Tatochenko V, et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospitalacquired rotavirus disease. Pediatr Infect Dis J 2006 Jan; 25 (1 Suppl.): S12-21 (Pubitemid 43884461)
33. Cunliffe NA, Booth JA, Elliot C, et al. Healthcareassociated viral gastroenteritis among children in a large pediatric hospital, United Kingdom. Emerg Infect Dis 2010 Jan; 16 (1): 55-62
34. Fischer TK, Bresee JS, Glass RI. Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine 2004; 22 Suppl. 1: S49-54 (Pubitemid 39575372)
35. Van Der Wielen M, Da Dalt L, Giaquinto C, et al. Impact of paediatric acute gastroenteritis (AGE) and rotavirus gastroenteritis (RVGE) on family life: the REVEAL study [abstract]. 25th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2007 May 2-4; Porto
36. Mast TC, DeMuro-Mercon C, Kelly CM, et al. The impact of rotavirus gastroenteritis on the family. BMC Pediatr 2009; 9: 11
37. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007 Nov 24; 370: 1757-63 (Pubitemid 350137490)
38. Ruiz-PalaciosGM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006 Jan; 354 (1): 11-22 (Pubitemid 43048947)
39. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004 Oct; 23 (10): 937-43 (Pubitemid 40812781)
40. Lambert SB, Faux CE, Hall L, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust 2009 Aug 3; 191 (3): 157-60
41. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010; 28: 7507-13
42. Braeckman T, Van Herck K, Raes M, et al. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011 Jan; 30 Suppl. 1: S21-4
43. Raes M, Strens D, Vergison A, et al. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J. Epub 2011 Mar 23
44. Bellido-Blasco JB, Sabater-Vidal S, Salvador-Ribera MDM, et al. Rotavirus vaccination effectiveness in Castellon (Spain): preliminary results using data from a specific diarrhoea study and the regional vaccine registry [abstract]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4-8; Nice
45. Martinon-Torres F, Bouzon-Alejandro M, Pertega Diaz S, et al. Prospective estimation of rotavirus vaccine effectiveness in Spain [abstract]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4-8; Nice
46. Rodrigues F, Iturriza M, Gonclaves G, et al. Large variations in rotavirus (RV) disease and strain diversity during low-level vaccine use in Portugal [abstract]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4-8; Nice
47. Plosker GL. Pentavalent rotavirus vaccine (RotaTeq-): a review of its use in the prevention of rotavirus gastroenteritis in Europe. Drugs 2010 Jun 18; 70 (9): 1165-88
48. Patel MM, Steele D, Gentsch JR, et al. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011 Jan; 30 Suppl. 1: S1-5
49. Vesikari T, Karvonen A, Prymula R, et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix coadministered with routine infant vaccines following the vaccination schedules in Europe. Vaccine 2010 Jun 7; 28: 5272-9
50. Glass RI, Bresee JS, Parashar UD, et al. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 2004; 363 (9420): 1547-50 (Pubitemid 38596836)
51. Giammanco MD, Coniglio MA, Pignato S, et al. An economic analysis of rotavirus vaccination in Italy. Vaccine 2009 Jun 12; 27 (29): 3904-11
52. Zomer TP, van Duynhoven YT, Mangen MJ, et al. Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 2008 Jul 4; 26 (29-30): 3757-64
53. Lorgelly PK, Joshi D, Gomara MI, et al. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008; 136 (1): 44-55
54. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and no medical care disease impact in Belgium. Med Decis Making 2009 Jan-2009 28; 29 (1): 33-50
55. Mangen MJ, van Duynhoven YT, Vennema H, et al. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine 2010 Mar 19; 28 (14): 2624-35
56. Martin A, Batty A, Roberts JA, et al. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 2009 Jul 16; 27 (33): 4520-8
57. Panatto D, Amicizia D, Ansaldi F, et al. Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy). Vaccine 2009; 27 (25-26): 3450-3
58. Newall AT, Beutels P, Macartney K, et al. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007 Dec 17; 25 (52): 8851-60 (Pubitemid 350192054)
59. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales: part II. The potential cost-effectiveness of vaccination. Vaccine 2007 May 16; 25 (20): 3971-9 (Pubitemid 46616994)
60. Chodick G, Waisbourd-Zinman O, Shalev V, et al. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel. Eur J Public Health 2009 Jun; 19 (3): 254-9
61. Goossens LM, Standaert B, Hartwig N, et al. The costutility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008 Feb 20; 26 (8): 1118-27
62. Jit M, Bilcke J, Mangen MJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009 Oct 19; 27 (44): 6121-8
63. Standaert B, Parez N, Tehard B, et al. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy 2008; 6 (4): 199-216
64. Melliez H, Levybruhl D, Boelle PY, et al. Cost and costeffectiveness of childhood vaccination against rotavirus in France. Vaccine 2008; 26 (5): 706-15
65. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 Jun [online]. Available from URL: http://www. nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune 2008.pdf [Accessed 2011 Jan 5]
66. Boersma C, Broere A, Postma MJ. Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis. Value Health 2010; 13 (6): 853-6
67. Jönsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4: 5-10 (Pubitemid 40066088)
68. Eichler H-G, Kong SX, Gerth WC, et al. Use of costeffectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7 (5): 518-28 (Pubitemid 39390832)
69. Bilcke J, Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009; 27 (4): 281-97
70. Nohynek H, Salo H, Renko M, et al. Finland introduces rotavirus vaccine into the national vaccination programme in September 2009. Euro Surveill 2009; 14 (35): 1-3
71. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26 (3): 191-215 (Pubitemid 351271379)
72. Standaert B, Gomez J, Axosta C, et al. Do we adequately model the benefit of rotavirus vaccination over time? [abstract no. PIN77 plus poster]. 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2010 Nov 6-9; Prague
73. Bauch CT, Anonychuk AM, Van Effelterre T, et al. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making 2009 Sep 31; 29 (5): 557-69
74. Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006; 26 (5): 434-46 (Pubitemid 44410295)
75. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003 Jan 28; 23 (1): 76-82 (Pubitemid 36133362)
76. Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States. Pediatr Infect Dis J 2011 Jan; 30 Suppl. 1: S56-60
77. Widdowson M-A, Steele D, Vojdani J, et al. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. J Infect Dis 2009; 200 Suppl. 1: S1-8
78. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesnt it increase at the rate of inflation? Arch Intern Med 2003 Jul 28; 163: 1637-41
79. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146 (4): 473-81